Overview

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Status:
Not yet recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma

Phase:

Early Phase 1

Details

Lead Sponsor:

The Affiliated Hospital of Xuzhou Medical University

Collaborator:

Guangzhou Bioresette Biomedical Technology Co., Ltd.

Treatments:

Cyclophosphamide
Fludarabine